# Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir

> **NCT03063879** · PHASE4 · COMPLETED · sponsor: **Tehran University of Medical Sciences** · enrollment: 95 (actual)

## Conditions studied

- Hepatitis C, Chronic
- Chronic Renal Failure

## Interventions

- **DRUG:** Sofosbuvir 400 mg and daclatasvir 60 mg

## Key facts

- **NCT ID:** NCT03063879
- **Lead sponsor:** Tehran University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-01
- **Primary completion:** 2018-09-01
- **Final completion:** 2019-02-01
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2019-09-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03063879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03063879, "Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03063879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*